Inhalation beta-2-agonists in cardiorespiratory pathology: pro-or anti-inflammatory effects?

Currently, the increase in comorbid pathology, including patients with bronchoobstructive and cardiovascular diseases remains an urgent problem. Therefore, there is a need not only for new approaches in the tactics of management and treatment of patients with combined cardiorespiratory pathology, but also a more complete understanding of the impact of existing bronchodilator therapy on comorbid pathology and the pathophysiological changes taking place in order to create a new approach to the diagnosis and selection of effective and optimal treatment. The article provides a review of the literature on the impact of beta-2-agonists on pro- and anti-inflammatory mechanisms in patients with bronchial obstruction, including cardiovascular disease.